The Association for the Cannabinoid Industry was launched at the end of October, providing a platform to aid the development of a legally compliant, socially responsible and innovative CBD industry. With the CBD market poised for further growth, Abi Millar sits down with the new trade group for a broad discussion about the future of this exciting but complex market.
The UK’s cannabidiol (CBD) market has exploded over the past few years, and shows no signs of slowing down. One of the main constituents of the cannabis sativa plant, CBD is sold in a wide range of forms, from sprays and gummies to CBD-infused hair treatments. Since it is mostly sold as a food supplement, not a medicine, manufacturers aren’t allowed to make health claims. That hasn’t deterred consumers, many of whom are using the products for therapeutic purposes.
However, confusion reigns over its legal status, and quality control is all but non-existent. In November, the Centre for Medicinal Cannabis (CMC) launched the Association for the Cannabinoid Industry (ACI), with a view to addressing poor practice throughout the industry. CMC/ACI development director Shomi Malik explains why there is such a pressing need for an organisation of this kind.
Read the rest of this article in the March 2020 edition of Pharma Technology Focus